Search

Your search keyword '"Odemis, Bulent"' showing total 20 results
Start Over Author "Odemis, Bulent" Search Limiters Full Text
20 results on '"Odemis, Bulent"'

9. Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection?

Author

Oztas, Erkin, primary, Kuzu, Ufuk Baris, additional, Zengin, Neslihan Inci, additional, Kalkan, Ismail Hakki, additional, Saygili, Fatih, additional, Yildiz, Hakan, additional, Celik, Huseyin Tugrul, additional, Akdogan, Meral, additional, Kilic, Mesut Yalin, additional, Koksal, Aydin Seref, additional, Odemis, Bulent, additional, Suna, Nuretdin, additional, and Kayacetin, Ertugrul, additional

Published
2015
Full Text
View/download PDF

13. The change in microorganisms reproducing in bile and blood culture and antibiotic susceptibility over the years

Author

Suna, Nuretdin, primary, Yıldız, Hakan, additional, Yuksel, Mahmut, additional, Parlak, Erkan, additional, Disibeyaz, Selcuk, additional, Odemis, Bulent, additional, Aydinli, Onur, additional, Bilge, Zulfikar, additional, Torun, Serkan, additional, Tezer Tekce, Ayse Yasemin, additional, Taskiran, Ismail, additional, and Sasmaz, Nurgul, additional

Published
2014
Full Text
View/download PDF

19. Rectal angiolipoma: a case report and review of literature.

Author

Kacar S, Kuran S, Temucin T, Odemis B, Karadeniz N, and Sasmaz N

Subjects
Aged, Angiolipoma pathology, Angiolipoma surgery, Colonoscopy, Endoscopy, Gastrointestinal, Female, Humans, Rectal Neoplasms pathology, Rectal Neoplasms surgery, Angiolipoma diagnosis, Rectal Neoplasms diagnosis
Abstract

Angiolipoma is a rare vascular variant of the benign lipomatous tumors and is generally seen in subcutaneous tissues. We report a 70-year-old female with abdominal distension not related to rectal small polypoid mass with peduncule described as angiolipoma by histologically, and review the literature.

Published
2007
Full Text
View/download PDF

20. Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).

Author

Oguz D, Cicek B, Filik L, Odemis B, Kilic M, Altintas E, Zengin N, and Altiparmak E

Subjects
Adult, Drug Resistance, Viral, Drug Therapy, Combination, Female, Genotype, Hepacivirus drug effects, Humans, Interferon alpha-2, Male, Middle Aged, Recombinant Proteins, Treatment Outcome, Amantadine administration & dosage, Antiviral Agents administration & dosage, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Ribavirin administration & dosage
Abstract

Aim: To evaluate the efficacy of amantadine plus interferon-alpha and ribavirin in non-responder patients with chronic hepatitis C., Methods: Twenty-six non-responder patients received the regimen of IFN-alpha-2a at a dose of 6 million units three times a week, 1 000-1 200 mg of ribavirin daily, and 200 mg of amantadine daily in divided doses over 48 wk. After the end of treatment, at the 72nd wk, a sustained viral response rate was determined., Results: An early (after 12 wk of therapy) response was seen in 34.6% (9/26) of patients. Response rate at the 24th wk was 42.3% (11/26). End of treatment response (ETR) was 53.8% (14/26). Sustained viral response (SVR) was 42.3% (11/26). There was a statistically significant difference between 0 and 12 wk (P = 0.04), 0 and 24 wk (P = 0.01), 0 and 48 wk (P = 0.00), and 0 and 72 wk (P = 0.001). No patient had severe adverse effects during the treatment., Conclusion: Combination regimen of interferon-alpha, ribavirin and amantadine can enhance sustained viral response on IFN-alpha and ribavirin non-responder patients with HCV. Triple therapy with amantadine should be evaluated in further studies.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results